PRIORITY Study Launches: Integrated Molecular-Digital Model for Cervical Cancer Screening — Implications for Australian Practice

References

1. 1.Pontificia Universidad Catolica de Chile. (2024). The PRIORITY Study in Cervical Cancer: A Prospective Multicenter Observational Evaluation. ClinicalTrials.gov. NCT07593066. https://clinicaltrials.gov/study/NCT07593066
2. 2.Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A. B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., Schiffman, M., & 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease, 24(2), 102-131. https://doi.org/10.1097/LGT.0000000000000525
3. 3.Louwers, J. A., Zaal, A., Kocken, M., ter Harmsel, W. A., Graziosi, G. C., Spruijt, J. W., Berkhof, J., Balas, C., & Papagiannakis, E. (2011). Dynamic spectral imaging colposcopy: higher sensitivity for detection of premalignant cervical lesions. BJOG, 118(3), 309-318. https://doi.org/10.1111/j.1471-0528.2011.02932.x
4. 4.Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016). Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2, 16086. https://doi.org/10.1038/nrdp.2016.86
5. 5.Fontham, E. T., Wolf, A. M., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. C. T., Walter, L. C., Kim, J. J., Andrews, K. S., DeSantis, C. E., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., Wender, R. C., & Smith, R. A. (2020). Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 70(5), 321-346. https://doi.org/10.3322/caac.21628
6. 6.Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
7. 7.Canfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., Burger, E. A., Martin, D., Nguyen, D. T. N., Bénard, É., Sy, S., Regan, C., Drolet, M., Gingras, G., Laprise, J. F., Torode, J., Smith, M. A., Fidarova, E., Trapani, D., ... Hutubessy, R. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. New England Journal of Medicine, 383(6), 549-559. https://doi.org/10.1056/NEJMoa1909006
8. 8.Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191-e203. https://doi.org/10.1016/S2214-109X(19)30482-6